A New Frontier in Market Listings
The New York Stock Exchange (NYSE) and Nasdaq are locked in a fierce competition to secure the listings of US-based marijuana companies, a sector previously sidelined by federal banking restrictions. Following a December 2025 executive order by President Trump that reclassified marijuana to a Schedule III controlled substance, and subsequent codification by the Department of Justice and the DEA in April 2026, the legal barrier to capital markets has begun to dissolve.
This regulatory shift allows US cannabis firms that register as medical companies with the DEA to finally access the public markets. With the industry projected to grow from $50 billion to nearly $100 billion annually by 2030, both exchanges are aggressively courting these firms to bolster their portfolios and capture a share of the burgeoning market.
The Battle for Market Share
The NYSE has secured an early advantage in this race. Jacksonville-based Trulieve and Long Beach-based Glass House Brands have both listed on the “Big Board” in recent months. Glass House Brands, which manufactures cannabis products, signaled that while they engaged with the NYSE early, Nasdaq also aggressively pursued the account, emphasizing the speed of their listing processes. A representative from Glass House noted that the competition between the two venues was palpable during their decision-making phase.
For exchanges, these listings are more than just revenue drivers; they are symbolic victories in a broader “listing war.” While Nasdaq has historically dominated the tech sector—hosting giants like Apple, Microsoft, and Nvidia—the NYSE maintains its stronghold in traditional finance, energy, and healthcare. Both venues are now looking to poach companies to diversify their offerings. Nasdaq’s recent success in convincing Walmart to switch from the NYSE remains the most significant shift in exchange history, underscoring the ongoing volatility in how blue-chip and emerging companies choose their listing homes.
Regulatory Outlook and Future Stakes
The competition is expected to intensify as industry executives anticipate further federal movement. Many in the cannabis sector believe the administration will soon move marijuana from Schedule III to Schedule IV or V. Such a reclassification would effectively serve as de facto legalization, allowing companies to fully utilize capital for recreational product development, including consumer staples like edibles and oils. As these companies prepare for public offerings, the choice of exchange will depend on a balance of listing fees—where Nasdaq is often more cost-effective—and the perceived prestige and liquidity offered by the NYSE.